CARDIOME PHARMA CORP news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

CRME 4.70 +0.04 (0.86%)
price chart
Cardiome Pharma Corp. Announces Voting Results
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies that will improve the quality of life and health of patients suffering from disease.
The $6.97 Million in Sales Expected for Cardiome Pharma Corporation (CRME ...  BangaloreWeekly
In Volatile Markets Do Analysts Think You Should Buy Cardiome Pharma ...  The De Soto Edge
Cardiome Pharma: The Pieces Are Coming Together
Cardiome (NASDAQ:CRME), like many other small cap drug development firms, has a storied history. In 2009, its AF drug Brinavess showed significant promise.
Premarket analyst action - healthcare
Cardiome Pharma (NASDAQ:CRME) upgraded to Buy with an $8 (70% upside) price target by Canaccord Genuity. Healthcare Trust (NYSE:HTA) upgraded to Strong Buy by Raymond James.
Cardiome Pharma Corp (CRME) Sees AroonUp Showing Strong Upward Momentum
Cardiome Pharma Corp (CRME) shares are showing strong upward momentum according to the Aroon indicator as the reading has climbed above 70.
Cardiome Pharma Corp. (NASDAQ:CRME) Earnings Forecast In Focus
For the next year, sell-side analysts are expecting EPS growth of 82.00% for Cardiome Pharma Corp. (NASDAQ:CRME). Analysts are expecting an EPS change of 42.20% for the current year.
Cardiome Pharma Corp. (TSX:COM) Investor Update & Valuation Review  JCTY News
Cardiome Pharma Corporation (CRME) Upgraded at Zacks Investment Research  Transcript Daily
BRIEF-Cardiome announces commercial launch of BRINAVESS in Canada
BRIEF-Cardiome announces commercial launch of BRINAVESS in Canada. 1 Min Read. June 12 (Reuters) - Cardiome Pharma Corp: * Cardiome announces commercial launch of Brinavess� (vernakalant hydrochloride) in Canada.
Cardiome Pharma Corporation (CRME) Given “Buy” Rating at Canaccord Genuity
Cardiome Pharma Corporation logo Canaccord Genuity reiterated their buy rating on shares of Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM) in a research report released on Monday morning, Marketbeat.com reports. They currently have a ...
Cardiome Pharma Corporation (NASDAQ:CRME) Earns “Buy” Rating from Canaccord ...  StockNewsTimes
Cardiome Pharma Corporation (CRME) Raised to Hold at Zacks Investment Research  Chaffey Breeze
Cardiome Reports Changes To Senior Management Team
VANCOUVER, May 16, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced a number of changes to its senior management team.
Cardiome Pharma's (CRME) CEO Bill Hunter on Q1 2017 Results - Earnings ...  Seeking Alpha
Cardiome Pharma (CRME) partner SteadyMed Ltd (STY) Submits TREVYENT NDA
Cardiome Pharma Corp. (NASDAQ: CRME) announced that partner SteadyMed Ltd (NASDAQ: STDY) submitted a New Drug Application (NDA) to the U.S.
Cardiome Pharma Corporation (CRME) Receives Consensus Recommendation of “Buy ...  Chaffey Breeze
Cardiome Pharma Corp. (CRME) stock could lead to a downward move  Voice Of Analysts
Cardiome Pharma (CRME) Receives Health Canada Approval of AGGRASTAT High Dose ...
Cardiome Pharma Corp. (NASDAQ: CRME) today announced that the Therapeutic Products Directorate (TPD) of Health Canada has approved the AGGRASTAT� (tirofiban hydrochloride) 25 mcg/kg (high) dose bolus ("HDB") regimen, as requested under the ...